Skip to main content
Aptose Biosciences Inc. logo

Aptose Biosciences Inc. — Investor Relations & Filings

Ticker · APS LEI · 5299003EUHV3CD08L949 TSX Professional, scientific and technical activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2025-06-26 Capital/Financing Update
Country CA Canada
Listing TSX APS

About Aptose Biosciences Inc.

https://www.aptose.com/

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines and first-in-class targeted agents for life-threatening cancers, focusing primarily on hematologic malignancies. The company's strategy involves creating differentiated therapies designed for safe single-agent efficacy across multiple indications and enhanced combination potential without overlapping toxicities. Key investigational agents include Tuspetinib, a potent oral Myeloid Kinase Inhibitor (MKI) targeting SYK, FLT3, and JAK, currently in Phase 1/2 for relapsed or refractory Acute Myeloid Leukemia (AML). The pipeline also features Luxeptinib, a dual-acting Kinome Inhibitor. Luxeptinib acts as a Lymphoid Kinome Inhibitor (LKI) in Phase 1a/b trials for B-cell malignancies (CLL/NHL) by non-covalently inhibiting BTK, and as an MKI in Phase 1a/b trials for AML and high-risk Myelodysplastic Syndromes (MDS) by potently inhibiting FLT3.

Recent filings

Filing Released Lang Actions
Material document(s).pdf
Capital/Financing Update Classification · 1% confidence The document is an executed facility agreement detailing the terms of a new US$8.5 million loan (interest rate, maturity, conditions precedent, events of default, security, etc.) between a lender and borrower. It is not an annual or interim financial report, not an earnings release or governance statement, and not a short publication announcement. Rather, it is a comprehensive financing contract, matching the description of a Capital/Financing Update. Therefore, it should be classified as CAP.
2025-06-26 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a Canadian Form 51-102F3 Material Change Report announcing that Aptose entered into a loan agreement (uncommitted facility of up to US$8.5M) for clinical development and working capital, detailing terms, security, covenants, related party status, and repayment. This is clearly a financing activity announcement rather than a full annual or interim report. It does not involve share issues but rather debt financing, fitting the "Capital/Financing Update" category (CAP).
2025-06-26 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release (“For Immediate Release”) announcing that Aptose entered into a new US$8.5 million loan agreement with Hanmi Pharmaceutical to fund clinical development of its drug. It discusses the terms of the facility, related-party exemptions under Multilateral Instrument 61-101, and use of proceeds. No financial statements or earnings data are presented, and it is not a shareholder vote or regulatory filing. It clearly falls under a Capital/Financing Update.
2025-06-20 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing two key items: a short-term cash advance (a financing activity) and a board resignation. The primary announcement pertains to securing a cash advance—a related-party financing transaction—fitting the definition of a Capital/Financing Update. It is not a full financial report, earnings release, or annual report, nor is it simply a notice of publication or regulatory filing. Therefore, it is classified as a Capital/Financing Update (CAP).
2025-06-17 English
Report of voting results.pdf
Management Reports Classification · 1% confidence The document is titled “Management Discussion and Analysis” (MD&A) for the three months ended March 31, 2025, prepared under National Instrument 51-102. It provides management’s narrative explanation of the interim financial results, business operations, and outlook. This corresponds to the “Management Reports” category (Code: MDA).
2025-05-29 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release announcing the detailed voting results from the company’s Annual and Special Meeting of shareholders, including director elections and other resolutions. This fits the category for Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.